RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing…
Read More

RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing…
Read More